Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBuecheler, Jakob W.en
dc.contributor.authorHoward, Christopher B.en
dc.contributor.authorde Bakker, Christopher J.en
dc.contributor.authorGoodall, Stephenen
dc.contributor.authorJones, Martina L.en
dc.contributor.authorWin, Thinzaren
dc.contributor.authorPeng, Taoen
dc.contributor.authorTan, Cher Hengen
dc.contributor.authorChopra, Akhilen
dc.contributor.authorMahler, Stephen M.en
dc.contributor.authorLim, Sierinen
dc.identifier.citationBuecheler, J. W., Howard, C. B., de Bakker, C. J., Goodall, S., Jones, M. L., Win, T., et al. (2015). Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells. Journal of chemical technology and biotechnology, 90(7), 1230-1236.en
dc.description.abstractBACKGROUND: A range of protein-based nanoparticles has been developed for cancer drug delivery and diagnostics. This includes the E2 protein derived from the pyruvate dehydrogenase complex in Geobacillus stearothermophilus which assembles into a 60-subunit protein cage structure that is capable of encapsulating cancer therapeutics. In this study antibody fragments targeting the epidermal growth factor receptor (EGFR) were tethered to the surface of E2 protein nanoparticles to determine whether the protein nanoparticles could be specifically targeted to EGFR overexpressing cancer cells. RESULTS: Variants of the anti-EGFR antibody fragment and the E2 protein containing specific cysteine residues (E2ΔN17A186C) were conjugated using a maleimide-specific crosslinker. Electron microscopy and dynamic light scattering analysis indicated that the cysteine modified E2 protein correctly assembled into a 25–30 nm particle. The conjugation of the anti-EGFR antibody fragment (26 kDa) with a subunit of the E2 protein (26 kDa) was confirmed by mass spectrometry with an estimated molecular weight of 52 kDa. The binding of the conjugated E2 particle to native EGFR on MDA MB 231 cells and recombinant EGFR was confirmed using flow cytometry and biolayer interferometry, respectively. CONCLUSIONS: In this study, proof-of-principle that an EGFR-targeting scFv can be stably conjugated to the cysteine variant E2ΔN17A186C protein nanoparticle without loss of targeting capability has been demonstrated. Conceptually scFv antibody fragments reactive with other important cancer targets could be utilized and presents the opportunity for generation of multi-targeted protein nanoparticles by conjugating various scFvs with different specificities on the same particle.en
dc.relation.ispartofseriesJournal of chemical technology and biotechnologyen
dc.rights© 2014 Society of Chemical Industry.en
dc.subjectDRNTU::Engineering::Chemical engineering::Biotechnologyen
dc.titleDevelopment of a protein nanoparticle platform for targeting EGFR expressing cancer cellsen
dc.typeJournal Articleen
dc.contributor.schoolSchool of Chemical and Biomedical Engineeringen
item.fulltextNo Fulltext-
Appears in Collections:SCBE Journal Articles


Updated on Sep 7, 2020


Updated on Feb 26, 2021

Page view(s)

Updated on Mar 1, 2021

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.